New York, NY—December 15, 2025, PhenoNet, a clinical-stage biotechnology company developing next-generation therapies for Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s Disease (AD), and related neurodegenerative disorders, has chosen Lange Neurology as a trial site for its phase IIB study to evaluate the effects of PHENOGENE-1A as an Adjuvant Treatment in subjects with mild to moderate ALS. 

“PHENOGENE-1A is a multifunctional therapy based on a repurposed drug with a known safety profile, formulated with novel targeted delivery technology. This approach is designed to achieve therapeutic concentrations in both blood and brain, where it acts on key mechanisms involved in neuroinflammation and neurodegeneration. Developed to slow or halt the progression of ALS, PHENOGENE-1A has demonstrated a favorable safety and tolerability profile in preclinical studies and early clinical testing. The treatment is designed to improve the quality of life for patients, their families, and caregivers.

“Addressing the triggers and progression of ALS with a multifunctional therapeutic approach offers a new strategy to modify the disease course,” said Dr. David R. Elmaleh, PhenoNet Founder and Chairman. ‘Very early intervention in patients with the first clinical signs of muscle function loss is key to preventing or delaying disease progression. Our in-vitro work, in-vivo ALS animal models, and data from a Phase II a cohort support advancing PHENOGENE-1A into this Phase IIb trial.’”

“Understanding and controlling neuroinflammation is widely thought to be an integral part of slowing the progression of ALS,” said Dr. Dale Lange. “We are excited to partner with PhenoNet to study the impact that PHENOGENE-1A will have on the progression of the illness in patients with ALS. ”